Trump Fast-Tracks Approval for Psychedelic Treatments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Should l Buy CMPS?
Source: Fool
- Accelerated Approval Process: Trump's order directs the FDA to reduce review times for certain psychedelic drugs from 6-10 months to just 1-2 months, significantly enhancing market appeal for psychedelic therapies and facilitating easier capital acquisition for related companies.
- Market Reaction: Following the new policy announcement, stocks of three biotech firms—Compass Pathways, Atai Beckley, and Definium Therapeutics—saw substantial gains on Monday, with Compass Pathways rising approximately 39% and Atai Beckley increasing by 32%, reflecting optimistic market sentiment towards psychedelic treatment prospects.
- Research Funding Support: The new order also allocates $50 million from the Department of Health and Human Services to advance private sector research into psychedelic therapies, providing additional resources for related companies to develop new treatments.
- Historical Return and Market Opportunities: Trump's directive signifies a new era for psychedelic treatments, potentially expediting the reclassification of currently Schedule I psychedelic compounds, and companies that can bring these new therapies to market first are likely to gain a competitive edge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.390
Low
8.00
Averages
18.43
High
40.00
Current: 9.390
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compass Pathways to Release Q1 Financial Results on May 13, 2026
- Earnings Release Schedule: Compass Pathways plc will announce its financial results for the first quarter ended March 31, 2026, on May 13, 2026, providing updates on recent developments that are expected to positively impact investor confidence.
- Conference Call Timing: Management will host a conference call at 8:00 am ET (1:00 pm UK) to discuss financial performance and future strategies, aiming to enhance market transparency and investor engagement.
- Webcast Availability: The call will be available via live webcast on the Compass Pathways website, with the recording archived for 30 days, ensuring that investors who cannot attend live can still access critical information, thereby improving information dissemination.
- Innovative Treatment Solutions: The COMP360 synthesized psilocybin treatment has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression, highlighting the company's leading position in this area and potentially attracting more investor interest.
See More
COMPASS PATHWAYS PLC: JEFFERIES BEGINS COVERAGE WITH A BUY RATING AND TARGET PRICE OF $18
Company Overview: Compass Pathways PLC is a mental health care company focused on developing innovative treatments for mental health conditions.
Recent Developments: The company has received coverage with a buy rating, indicating positive investor sentiment and confidence in its future performance.
Target Price: Analysts have set a target price of $18 for Compass Pathways shares, suggesting potential growth in value.
Market Position: The company's initiatives and market strategies are aimed at addressing significant unmet needs in mental health treatment.
See More
CMPS Stock Surges 41% This Week, Poised for Record Gains
- FDA Priority Review: Compass Pathways' COMP360 has been granted the Commissioner's National Priority Voucher by the FDA, allowing for a dramatically shortened review period of 1-2 months for its treatment-resistant depression application, thereby accelerating the market entry of this innovative therapy and enhancing the company's competitive edge.
- Analyst Ratings Optimistic: According to Koyfin, 11 out of 12 analysts covering CMPS rate it 'Buy' or higher, indicating strong market confidence in COMP360, with a projected 141% upside potential, which is likely to attract further investor interest.
- Strong Stock Performance: CMPS stock has surged 45% this week, with an additional 5.5% increase on Friday, marking the best week in the company's history and reflecting positive market expectations for its drug development, potentially drawing more capital inflows.
- High Market Sentiment: On Stocktwits, retail investor sentiment around CMPS remains in the 'extremely bullish' territory with extremely high message volume, indicating a strong optimistic outlook among investors regarding the company's future developments, further fueling the stock's rise.
See More
Compass Secures FDA Priority Review Support for COMP360
- FDA Priority Review: Compass Pathways has received a rolling NDA submission and review request from the FDA based on positive data from two large Phase 3 clinical trials, marking a significant advancement in the treatment of treatment-resistant depression and potentially accelerating its product launch timeline.
- National Priority Voucher Program: COMP360 has been selected for the FDA's National Priority Voucher program, which allows for a shortened review time of 1-2 months, enhancing Compass's market competitiveness and providing patients with quicker access to innovative treatment options that are urgently needed.
- Clinical Trial Results: COMP360 has demonstrated significant clinical effects in over 1,000 patients with treatment-resistant depression, showing effects as quickly as one day after administration, with durability lasting at least six months for those achieving a clinically meaningful response, offering new hope for patients.
- Urgent Market Demand: With approximately 4 million patients in the U.S. affected by treatment-resistant depression, Compass's innovative treatment could not only improve quality of life for these individuals but also potentially become the first breakthrough therapy in this field, addressing the growing market demand.
See More
COMP360 Receives FDA Priority Review Voucher
- FDA Priority Review: COMPASS Pathways' COMP360 has received an FDA Commissioner's National Priority Voucher, allowing for a review period of one to two months post-NDA submission, significantly shortening the approval timeline and enhancing market competitiveness.
- Rolling Submission Approval: The FDA has granted COMPASS Pathways' request for a rolling submission, enabling the company to submit data incrementally during the NDA process, thereby accelerating communication with the FDA and optimizing the approval workflow.
- Clinical Trial Success: In February, COMP360 achieved its primary endpoint in a late-stage trial, demonstrating its efficacy in treating treatment-resistant depression, which lays a solid foundation for future market launch efforts.
- Positive Market Outlook: As a leader in the psychedelic market, COMPASS Pathways is expected to attract increased investor interest following the FDA's favorable feedback and successful clinical trials, likely driving the company's stock price upward.
See More
FDA Accelerates Development of Psychedelic Treatments for Mental Health
- Regulatory Push: The FDA has announced plans to accelerate the development of psychedelic treatments to address serious mental health issues, particularly post-traumatic stress disorder and treatment-resistant depression, indicating strong support for innovative therapies.
- Presidential Directive: Last week, President Trump signed an executive order directing health agencies to expedite research on psychedelic substances like psilocybin, MDMA, and ibogaine, aiming to swiftly tackle the national mental health crisis, especially for veterans.
- Market Reaction: Following the FDA's new policy, shares of Compass Pathways Plc. (CMPS), Helus Pharma Inc. (HELP), and Enveric Biosciences Inc. (ENVB) rose between 2% and 7% in Friday's opening trade, reflecting investor optimism about the psychedelic drug market's potential.
- Industry Outlook: This FDA initiative not only paves the way for clinical applications of psychedelics but may also encourage more companies to enter this emerging market, thereby driving innovation and growth among related firms.
See More
Compass Pathways to Release Q1 Financial Results on May 13, 2026
- Earnings Release Schedule: Compass Pathways plc will announce its financial results for the first quarter ended March 31, 2026, on May 13, 2026, providing updates on recent developments that are expected to positively impact investor confidence.
- Conference Call Timing: Management will host a conference call at 8:00 am ET (1:00 pm UK) to discuss financial performance and future strategies, aiming to enhance market transparency and investor engagement.
- Webcast Availability: The call will be available via live webcast on the Compass Pathways website, with the recording archived for 30 days, ensuring that investors who cannot attend live can still access critical information, thereby improving information dissemination.
- Innovative Treatment Solutions: The COMP360 synthesized psilocybin treatment has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression, highlighting the company's leading position in this area and potentially attracting more investor interest.
See More
COMPASS PATHWAYS PLC: JEFFERIES BEGINS COVERAGE WITH A BUY RATING AND TARGET PRICE OF $18
Company Overview: Compass Pathways PLC is a mental health care company focused on developing innovative treatments for mental health conditions.
Recent Developments: The company has received coverage with a buy rating, indicating positive investor sentiment and confidence in its future performance.
Target Price: Analysts have set a target price of $18 for Compass Pathways shares, suggesting potential growth in value.
Market Position: The company's initiatives and market strategies are aimed at addressing significant unmet needs in mental health treatment.
See More
CMPS Stock Surges 41% This Week, Poised for Record Gains
- FDA Priority Review: Compass Pathways' COMP360 has been granted the Commissioner's National Priority Voucher by the FDA, allowing for a dramatically shortened review period of 1-2 months for its treatment-resistant depression application, thereby accelerating the market entry of this innovative therapy and enhancing the company's competitive edge.
- Analyst Ratings Optimistic: According to Koyfin, 11 out of 12 analysts covering CMPS rate it 'Buy' or higher, indicating strong market confidence in COMP360, with a projected 141% upside potential, which is likely to attract further investor interest.
- Strong Stock Performance: CMPS stock has surged 45% this week, with an additional 5.5% increase on Friday, marking the best week in the company's history and reflecting positive market expectations for its drug development, potentially drawing more capital inflows.
- High Market Sentiment: On Stocktwits, retail investor sentiment around CMPS remains in the 'extremely bullish' territory with extremely high message volume, indicating a strong optimistic outlook among investors regarding the company's future developments, further fueling the stock's rise.
See More
Compass Secures FDA Priority Review Support for COMP360
- FDA Priority Review: Compass Pathways has received a rolling NDA submission and review request from the FDA based on positive data from two large Phase 3 clinical trials, marking a significant advancement in the treatment of treatment-resistant depression and potentially accelerating its product launch timeline.
- National Priority Voucher Program: COMP360 has been selected for the FDA's National Priority Voucher program, which allows for a shortened review time of 1-2 months, enhancing Compass's market competitiveness and providing patients with quicker access to innovative treatment options that are urgently needed.
- Clinical Trial Results: COMP360 has demonstrated significant clinical effects in over 1,000 patients with treatment-resistant depression, showing effects as quickly as one day after administration, with durability lasting at least six months for those achieving a clinically meaningful response, offering new hope for patients.
- Urgent Market Demand: With approximately 4 million patients in the U.S. affected by treatment-resistant depression, Compass's innovative treatment could not only improve quality of life for these individuals but also potentially become the first breakthrough therapy in this field, addressing the growing market demand.
See More
COMP360 Receives FDA Priority Review Voucher
- FDA Priority Review: COMPASS Pathways' COMP360 has received an FDA Commissioner's National Priority Voucher, allowing for a review period of one to two months post-NDA submission, significantly shortening the approval timeline and enhancing market competitiveness.
- Rolling Submission Approval: The FDA has granted COMPASS Pathways' request for a rolling submission, enabling the company to submit data incrementally during the NDA process, thereby accelerating communication with the FDA and optimizing the approval workflow.
- Clinical Trial Success: In February, COMP360 achieved its primary endpoint in a late-stage trial, demonstrating its efficacy in treating treatment-resistant depression, which lays a solid foundation for future market launch efforts.
- Positive Market Outlook: As a leader in the psychedelic market, COMPASS Pathways is expected to attract increased investor interest following the FDA's favorable feedback and successful clinical trials, likely driving the company's stock price upward.
See More
FDA Accelerates Development of Psychedelic Treatments for Mental Health
- Regulatory Push: The FDA has announced plans to accelerate the development of psychedelic treatments to address serious mental health issues, particularly post-traumatic stress disorder and treatment-resistant depression, indicating strong support for innovative therapies.
- Presidential Directive: Last week, President Trump signed an executive order directing health agencies to expedite research on psychedelic substances like psilocybin, MDMA, and ibogaine, aiming to swiftly tackle the national mental health crisis, especially for veterans.
- Market Reaction: Following the FDA's new policy, shares of Compass Pathways Plc. (CMPS), Helus Pharma Inc. (HELP), and Enveric Biosciences Inc. (ENVB) rose between 2% and 7% in Friday's opening trade, reflecting investor optimism about the psychedelic drug market's potential.
- Industry Outlook: This FDA initiative not only paves the way for clinical applications of psychedelics but may also encourage more companies to enter this emerging market, thereby driving innovation and growth among related firms.
See More
